Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma.
Rosenberg AJ, Agrawal N, Pearson AT, Gooi Z, Blair E, Portugal L, Cursio JF, Juloori A, Chin J, Rouse K, Villaflor VM, Seiwert TY, Izumchenko E, Lingen MW, Haraf DJ, Vokes EE. Rosenberg AJ, et al. Among authors: chin j. Br J Cancer. 2022 Nov;127(8):1497-1506. doi: 10.1038/s41416-022-01941-0. Epub 2022 Aug 9. Br J Cancer. 2022. PMID: 35945244 Free PMC article. Clinical Trial.
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
Rosenberg AJ, Agrawal N, Pearson A, Gooi Z, Blair E, Cursio J, Juloori A, Ginat D, Howard A, Chin J, Kochanny S, Foster C, Cipriani N, Lingen M, Izumchenko E, Seiwert TY, Haraf D, Vokes EE. Rosenberg AJ, et al. Among authors: chin j. Oral Oncol. 2021 Nov;122:105566. doi: 10.1016/j.oraloncology.2021.105566. Epub 2021 Oct 18. Oral Oncol. 2021. PMID: 34662771 Free PMC article. Clinical Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Rosenberg AJ, Agrawal N, Juloori A, Cursio J, Gooi Z, Blair E, Chin J, Ginat D, Pasternak-Wise O, Hasina R, Starus A, Jones FS, Izumchenko E, MacCracken E, Wolk R, Cipriani N, Lingen MW, Pearson AT, Seiwert TY, Haraf DJ, Vokes EE. Rosenberg AJ, et al. Among authors: chin j. JAMA Oncol. 2024 Jul 1;10(7):923-931. doi: 10.1001/jamaoncol.2024.1530. JAMA Oncol. 2024. PMID: 38842838 Clinical Trial.
Group 1 innate lymphoid cells protect liver transplants from ischemia-reperfusion injury via an interferon-γ-mediated pathway.
Kojima H, Morinelli TA, Wang Y, Chin JL, Meyer AS, Kao YC, Kadono K, Yao S, Torgerson T, Dery KJ, Bhat A, Reed EF, Kaldas FM, van der Windt DJ, Farmer DG, Kupiec-Weglinski JW, Zhai Y. Kojima H, et al. Among authors: chin jl. Am J Transplant. 2024 Dec 28:S1600-6135(24)00793-7. doi: 10.1016/j.ajt.2024.11.035. Online ahead of print. Am J Transplant. 2024. PMID: 39736469
2,213 results